Exploring how NRF2 affects metabolism in lung cancer
Official title: Investigation of NRF2-Dependent Metabolic Liabilities
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10928697 · Data updated 2026-11-12
This study is looking at how a protein called NRF2 affects the way non-small cell lung cancer grows and survives, using special mice to see how changes in this protein and its partner KEAP1 impact cancer, with the goal of finding better treatments by understanding how tumors produce an important antioxidant called glutathione.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $360,169 |
| NIH project number | 5R37CA230042-07 |
| Project ID | NIH-10928697 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer, particularly those with mutations in NRF2 or KEAP1.
✕Less likely to help
Patients with other types of lung cancer or those without NRF2 or KEAP1 mutations may not benefit from this research.
What this research studies
This research investigates the role of NRF2, a protein that influences metabolic changes in non-small cell lung cancer (NSCLC). By studying genetically modified mouse models, the team aims to understand how mutations in NRF2 and its regulator KEAP1 contribute to cancer growth and survival. The research focuses on the production of glutathione, an important antioxidant, and how its synthesis is altered in tumors. Through advanced metabolomics techniques, the study seeks to uncover the mechanisms behind these metabolic changes and their implications for cancer therapy.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies targeting metabolic pathways in lung cancer.
How similar studies have gone: Previous research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach may yield significant insights.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Denicola, Gina Marie — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Denicola, Gina Marie
Related research
Other NIH-funded projects on the same topics.
-
Central Laboratory Core for Advanced Cancer Research
A central laboratory core provides shared, specialized services to cancer researchers to help advance patient-focused studies.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Administration & Coordinating Core
This grant funds a central hub to help coordinate cancer research efforts at a major cancer center so researchers can work together more efficiently.
-
Developmental and Career Enhancement Core (for researchers)
A dedicated program to help researchers build skills and advance their careers over several years.
-
Central Laboratory Core for Cancer Research
A cancer research center is funding a shared lab core to support various studies over the next five years.
-
Exploring how HPV-related cancers affect people living with HIV and what helps survival
A patient-friendly look at a project studying how HPV-related cancers and HIV interact and what factors influence survival.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.